{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Polymorphic+Post-Transplant+Lymphoproliferative+Disorder",
    "query": {
      "condition": "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T01:01:31.716Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06723457",
      "title": "Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2025-07-25",
      "completion_date": "2029-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T01:01:31.716Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06723457"
    },
    {
      "nct_id": "NCT02900976",
      "title": "Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EBV-Related Post-Transplant Lymphoproliferative Disorder",
        "Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-03-22",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-05-22T01:01:31.716Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900976"
    },
    {
      "nct_id": "NCT06672705",
      "title": "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder",
        "EBV-Related Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Timothy Voorhees",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2025-06-16",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-05-22T01:01:31.716Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Columbus, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06672705"
    }
  ]
}